A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

被引：0
|
作者：
Fowler, Nathan [1 ]
McLaughlin, Peter [1 ]
Hagemeister, Fredrick B. [1 ]
Kwak, Larry [1 ]
Fanale, Michelle [1 ]
Neelapu, Sattva [1 ]
Fayad, Luis [1 ]
Pro, Barbara [1 ]
Sergent, Crystal [1 ]
White, Shana R. S. [1 ]
Samaniego, Felipe [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：683 / 683
页数：1
相关论文
共 50 条
  • [1] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma
    Fowler, N. H.
    McLaughlin, P.
    Kwak, L.
    Hagemeister, F.
    Fanale, M.
    Fayad, L.
    Pro, B.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Complete response rates with lenalidonide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.
    Fowler, N. H.
    McLaughlin, P.
    Hagemeister, F. B.
    Kwak, L. W.
    Fanaie, M. A.
    Neelapu, S. S.
    Fayad, L.
    Orlowski, R. Z.
    Wang, M.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Chemokine upregulation in response to rituximab in B-cell non-Hodgkin's lymphoma.
    Ansell, SM
    Tschumper, RC
    Witzig, TE
    Kurtin, PJ
    Jelinek, DF
    BLOOD, 1999, 94 (10) : 86A - 86A
  • [4] Rituximab therapy for indolent non-Hodgkin's lymphoma
    Hagenbeek, A
    Czuczman, MS
    Ghielmini, M
    Herold, M
    Kimby, E
    Solal-Céligny, P
    Unterhalt, M
    ANTI-CANCER DRUGS, 2002, 13 : S11 - S17
  • [5] A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
    Witzig, T. E.
    Nowakowski, G. S.
    Habermann, T. M.
    Goy, A.
    Hernandez-Ilizaliturri, F. J.
    Chiappella, A.
    Vitolo, U.
    Fowler, N.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1667 - 1677
  • [6] Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
    Murali Kesavan
    Toby A. Eyre
    Graham P. Collins
    Current Hematologic Malignancy Reports, 2019, 14 : 207 - 218
  • [7] Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
    Kesavan, Murali
    Eyre, Toby A.
    Collins, Graham P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (04) : 207 - 218
  • [8] Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    Tobinai, Kensei
    Ishizawa, Ken-ichi
    Ogura, Michinori
    Itoh, Kuniaki
    Morishima, Yasuo
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Yamamoto, Joji
    Uchida, Toshiki
    Nakata, Masanobu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Hayashi, Masaki
    Hotta, Tomomitsu
    CANCER SCIENCE, 2009, 100 (10) : 1951 - 1956
  • [9] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma.
    Van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, Katherine Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    BLOOD, 2006, 108 (11) : 766A - 766A
  • [10] Combination of plitidepsin and rituximab is effective for treatment of rituximab resistant Non-Hodgkin's B-cell lymphoma
    Barboza, Nora
    Medina, Daniel
    Budak, Tulin
    Aracil, Miguel
    Paz, Me
    Bertino, Joseph
    Banerjee, Debabrata
    CANCER RESEARCH, 2009, 69
12345